EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

iBio, Inc. (IBIO) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of iBio, Inc. $1.05, price $1.13, upside -7.4%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US4510337086

II iBio, Inc. logo Thin data Oct 4, 2026

iBio, Inc.

IBIO · US

Low PriorityFair Value upside is limited and quality is weak.

Low debt
Fair value $1.05 · Fairly valued (−7.4%)
Mixed vs. peers (3/6)
Quality 22/100
Weak Growth (revenue 5y −46.9 %/yr in USD)
Negative free cash flow
Narrow moat 5/100
Thin data
⚠ Dilution
Watch iBio, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$760.00 $0.5700 Fair Value $1.05 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

60‑month range $0.5700 – $760.00 · fair‑value band $0.6885 – $1.30 · the $1.13 price screens above the $1.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 4, 2026.

Follow iBio, Inc. Common Stock in your weekly email

Every Wednesday you see whether iBio, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.

Show more

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Stock analysis

iBio, Inc. Common Stock (IBIO) currently trades at $1.13, while our model-based Fair Value estimate is $1.05, so the stock looks roughly fairly valued today (gap 8.0%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.6885 (bear) to $1.30 (bull), the price of $1.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

iBio, Inc. Common Stock reported revenue of $100K in FY2026 versus $1.9M in FY2022, a compound −52.0%/yr. Reported net income was −$33.0M in FY2026.

Key figures

Market cap $118M · EPS (TTM) $−0.3200 · Return on equity −65.7% · Return on assets (EBIT) −54.9% · Operating margin −30,138% · Revenue (TTM) $100K · Free cash flow −$23.8M · Net cash $54.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 63% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −7%, IBIO screens richer than that median.

Fair Value models

Bear $0.6885 Fair Value $1.05 Bull $1.30
Price $1.13 · Upside -7.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.6700 $0.8900 $1.33 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.6700 $0.8900 $1.33 54

Open the full fair value analysis →

Notify me when IBIO reaches fair value

Put IBIO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 22/100

Of which business quality 22 · Market factors (momentum, volatility) 33

Profitability 0
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 34
Price trend over the last 3–12 months (market factor)
52W Momentum 45
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−75.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−46.9%
Start year 2021 (pandemic). Over 10 years: −20.1% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,312.1% (2021) → −35,141.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch IBIO, get fair value alerts →

Compare iBio, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −7.5% · Above median
Profitability
Return on assets −30.8% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.37× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

iBio, Inc. Common Stock · Fair Value
$1.05 −7%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "iBio, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/IBIO

Frequently asked questions

Is iBio, Inc. (IBIO) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $1.05 versus a price of $1.13, about −7% upside (fairly valued).
What is the fair value of IBIO?
Our model-based fair value for iBio, Inc. Common Stock is $1.05 (as of Oct 4, 2026), built from audited fundamentals. The current price: $1.13.
What is the quality score of IBIO?
iBio, Inc. Common Stock has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iBio, Inc. (IBIO)?
Our model-based price target is the fair value of $1.05 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario $0.6885, optimistic scenario $1.30. It is a calculation from audited fundamentals, not an analyst target.
What is the iBio, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $1.05, about −7% upside versus a price of $1.13 (fairly valued). Cautious scenario $0.6885, optimistic scenario $1.30. The calculation is refreshed regularly with new filings.
What is the revenue of iBio, Inc. (IBIO)?
iBio, Inc. Common Stock reported trailing-twelve-month revenue of about $100K (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of iBio, Inc. (IBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iBio, Inc. Common Stock it is $1.05 per share (as of Oct 4, 2026), against a price of $1.13. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is iBio, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Oct 4, 2026, IBIO trades above its calculated fair value: price $1.13, fair value $1.05, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBIO?
No. The price is what the market pays today ($1.13); the fair value is what the company's own numbers justify ($1.05). For iBio, Inc. Common Stock the two are $0.0840 per share apart. That gap is exactly why we show both numbers side by side.
How much is iBio, Inc. Common Stock worth?
The market values iBio, Inc. Common Stock at about $118M (market capitalisation, as of Oct 4, 2026). Per share that is $1.13; our models calculate a fair value of $1.05 per share.
What do the bullish and bearish scenarios say about IBIO?
Our models span a range for iBio, Inc. Common Stock: cautious scenario $0.6885, base $1.05, optimistic $1.30 per share (as of Oct 4, 2026, price $1.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of iBio, Inc. (IBIO)?
Balance-sheet figures for iBio, Inc. Common Stock (as of Oct 4, 2026): return on equity −65.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is IBIO from its 52-week high?
iBio, Inc. Common Stock trades at $1.13, about 63% below its 52-week high of $3.07 and 43% above the low of $0.7900 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.05 is for.
Which stocks are comparable to iBio, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iBio, Inc. Common Stock stock attractive at the current price?
The data as of Oct 4, 2026: price $1.13, calculated fair value $1.05 (−7%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IBIO calculated?
We run iBio, Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.05, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. iBio, Inc. Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iBio, Inc. (IBIO)?
The closing price on Oct 2, 2026 was $1.13. Our model-based fair value is $1.05, about −7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iBio, Inc. Common Stock right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.6885 to $1.30) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of iBio, Inc. Common Stock

How large is the market capitalisation of iBio, Inc. (IBIO)?
The market capitalisation of iBio, Inc. Common Stock is $118M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of iBio, Inc. (IBIO)?
Earnings per share at iBio, Inc. Common Stock are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of iBio, Inc. (IBIO)?
The return on equity (ROE) of iBio, Inc. Common Stock is −65.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iBio, Inc. (IBIO)?
On an EBIT basis the return on assets of iBio, Inc. Common Stock is −54.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iBio, Inc. (IBIO)?
The operating margin of iBio, Inc. Common Stock is −30,138% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does iBio, Inc. (IBIO) generate?
The free cash flow of iBio, Inc. Common Stock is −$23.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does iBio, Inc. (IBIO) hold?
iBio, Inc. Common Stock holds more cash than debt, $54.2M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch iBio, Inc. Common Stock in the live analysis

One click puts iBio, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.